Project 2: Mitigation Of Neurological Damage Following Seizures

In the case of accidental or terrorist release of organophosphate (OP) anticholinesterase inhibitors or the GABAA antagonist TETS, it is likely medical support will be unavailable for the first 30 to 60 minutes after people start exhibiting seizures. This means the processes that promote brain damage will have already been set in motion. The objective of project 2 is to identify therapies for treating the delayed neurological effects of intoxication with these chemical threat agents. Another goal is to develop non-invasive in vivo imaging strategies to longitudinally monitor the progression of neurological damage and the effectiveness of treatment.

To date, we have interacted with Project 1 to develop a mouse model of TETS-induced status epilepticus (SE) and we have refine a rat model of DFP-induced SE for use in neuroprotection studies. Using these preclinical models, Projects 1 and 2 showed that allopregnanolone, a positive allosteric modulator of GABAA receptors, was a superior countermeasure for TETS-induced SE in mice, particularly when administered at delayed times. We are currently examining allopregnanolone in combination with midazolam for efficacy in terminating seizures and/or protecting against persistent neuropathology in the rat DFP model. We are also screening candidate neuroprotectants that significantly reduce neuropathology when administered at delayed time post-DFP exposure.


Related Publications

Pessah IN, Rogawski MA, Tancredi DJ, Wulff H, Zolkowska D, Bruun DA, Hammock BD, Lein PJ.
Ann N Y Acad Sci. 2016. doi: 10.1111/nyas.13137
PubMed PMID: 
Bruun DA, Cao Z, Inceoglu B, Vito ST, Austin AT, Hulsizer S, Hammock BD, Tancredi DJ, Rogawski MA, Pessah IN, Lein PJ
Neuropharmacology. 2015;95:332-42. doi: 10.1016/j.neuropharm.2015.03.035
PubMed PMID: 
PubMed PMCID: 
Vito ST, Banks CN, Inceoglu B, Bruun DA, Zolkowska D, McCoy MR, Rogawski MA, Hammock BD, Lein PJ
Toxicol Appl Pharmacol (in press)
Li Y, Lein PJ, Liu C, Bruun DA, Giulivi C, Ford G, Tewolde T, Ross-Inta C, Ford BD
Toxicol Appl Pharmacol 262(2):194-204